Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions HER2-positive Breast Cancer
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aimed to evaluate the feasibility and safety, and to observe early efficacy signals of the focused ultrasound mediated drug delivery system combined with SonoVue® in patients with HER2-positive breast cancer receiving neoadjuvant therapy by comparing its pathological complete response (pCR) rate with a matched historical cohort of HER2-positive breast cancer patients treated at our center.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Focused Ultrasound-Mediated Targeted Drug Delivery Combined with Neoadjuvant Therapy — Participants will undergo six cycles of focused ultrasound-mediated targeted drug delivery combined with neoadjuvant therapy. The ultrasound parameters are set as follows: ultrasound power 9 W (acoustic pressure 3 MPa), frequency 1 MHz, pulse duration 100 μs, pulse repetition frequency 100 Hz, with 5 treatment cycles per single point. During each treatment session, 2.5 mL of SonoVue® ultrasound contrast agent microbubbles is injected via the cubital vein, followed by a 5 mL normal saline flush. Subsequently, 2.5 mL of SonoVue® microbubbles are administered every 2 minutes, with a total injection volume of 15 mL throughout the procedure.

Primary Outcomes

  • Pathological Complete Response rate (18 weeks from the enrollment, after the surgey)
  • Tumor Pathological Complete Response (18 weeks from the enllorment, after the surgey)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-01-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • Yiding Chen (PRINCIPAL_INVESTIGATOR) - The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Contact Information
Study Contact:
Yong Shen
+86-13616555799
shenyong@zju.edu.cn
Yong Shen
+86-13616555799
shenyong@zju.edu.cn
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Interventions
  • Device: Focused Ultrasound-Mediated Targeted Drug Delivery Combined with Neoadjuvant Therapy — Participants will undergo six cycles of focused ultrasound-mediated targeted drug delivery combined with neoadjuvant therapy. The ultrasound parameters are set as follows: ultrasound power 9 W (acoustic pressure 3 MPa), frequency 1 MHz, pulse duration 100 μs, pulse repetition frequency 100 Hz, with 5 treatment cycles per single point. During each treatment session, 2.5 mL of SonoVue® ultrasound contrast agent microbubbles is injected via the cubital vein, followed by a 5 mL normal saline flush. Subsequently, 2.5 mL of SonoVue® microbubbles are administered every 2 minutes, with a total injection volume of 15 mL throughout the procedure.
Study Locations (1 sites)
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-70 years. 2. Histologically confirmed HER2 positive breast cancer, with indication for neoadjuvant chemotherapy, and scheduled to receive the T(P)CbHP neoadjuvant regimen. 3. TNM stage T2N0-2M0. 4. Adequate bone marrow reserve (ANC \>1.5×10⁹/L, platelets \>100×10⁹/L). 5. Normal liver function (ALAT, ASAT, and bilirubin \<2.5× upper limit of normal). 6. Adequate renal function (creatinine clearance \>50 mL/min). 7. Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography or MUGA. 8. No psychological, family, social, or geographical conditions that would compromise compliance with the study protocol and follow-up schedule. 9. No medical conditions that would place the subject at undue risk. 10. Written informed consent signed by the subject. Exclusion Criteria: 1. Prior history of radiotherapy or chemotherapy. 2. Pregnant or lactating patients. 3. Presence of distant metastasis. 4. Bilateral invasive breast cancer. 5. Concurrent administration of other anticancer therapies or another investigational agent. 6. inadequate physical tolerance, including significant cardiovascular, hepatic, or renal dysfunction, massive ascites, intestinal obstruction, severe infection, high fever, as well as water-electrolyte and acid-base imbalance. 7. Patients with known hyper sensitivity to SonoVue®.
Conditions Salt-Sensitivity of Blood Pressure, Hype...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study Title: Determining the Presence of Salt Sensitivity in Individuals With Elevated Blood Pressure Through Dietary Salt Interventions: A Series of N-of-1 Trials Objective: To evaluate whether there are differences in blood pressure responses to dietary sodium intake between salt-sensitive and salt-resistant individuals, as identified through a salt sensitivity test. The study will use repeated dietary interventions with varying sodium content (high-sodium, low-sodium) to assess blood pressure responses in each individual, aiming to determine whether salt sensitivity is a present characteristic. Study Design: This study will utilize an N-of-1 randomized controlled trial design. It consists of two phases: Salt Sensitivity Screening: A 2-week chronic salt-loading test will be used to identify salt-sensitive and salt-resistant individuals. N-of-1 Trial: The identified salt-sensitive and salt-resistant individuals will undergo a 6-week N-of-1 trial, consisting of three cycles, with each cycle including one week of low-sodium diet and one week of high-sodium diet. This design aims to assess individual blood pressure responses to changes in sodium intake. Sample Size: A total of 72 participants will be recruited for the salt sensitivity screening, with an expected 24 participants proceeding to the N-of-1 trial. Study Population: Healthy individuals aged 20-65 years, not on antihypertensive medication or with a stable regimen for at least 3 months, with systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg, who are able to eat at the research center. Primary Outcome: Reproducibility of salt sensitivity response classification. Secondary Outcomes: Changes in mean arterial pressure, systolic and diastolic blood pressure; exploratory outcomes such as sleep, mood, gut microbiome, metabolomics; safety outcomes including hypotension and hyponatremia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Other: High-Sodium Diet — Daily dietary salt intake: 12 g (sodium 200 mmol)
  • Other: Low-Sodium Diet — Daily dietary salt intake: 5 g (sodium 85 mmol)

Primary Outcomes

  • Reproducibility of salt-sensitivity classification (Salt-sensitivity test: baseline through Day 14 N-of-1 trial: baseline through Day 42)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-02
Completion: 2026-11-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Principal Investigators:
  • Yifang Yuan (PRINCIPAL_INVESTIGATOR) - Peking University
Contact Information
Study Contact:
Yifang Yuan
0086-17310387323
yyfjulie@163.com
Yifang Yuan
0086-17310387323
yyfjulie@163.com
Peking University
Interventions
  • Other: High-Sodium Diet — Daily dietary salt intake: 12 g (sodium 200 mmol)
  • Other: Low-Sodium Diet — Daily dietary salt intake: 5 g (sodium 85 mmol)
Study Locations (1 sites)
Peking University, Beijing, China
Eligibility Criteria
Phase 1: Salt Sensitivity Screening Inclusion: 1. Signed informed consent for the salt sensitivity test. 2. Systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg. 3. Not taking any antihypertensive medication, or have had a stable antihypertensive regimen for the past three months and agree not to adjust their medication during the study period. 4. Able to comply with consuming the study-provided diet throughout the study period. Exclusion: 1. Special dietary requirements, such as allergies to common foods (e.g., eggs, seafood, peanuts), or conditions like asthma, irritable bowel syndrome, lactose intolerance, chronic kidney disease stage 4 or higher, history of gastrointestinal surgery, or special dietary needs due to other illnesses, surgery, or weight loss. 2. Diagnosed with chronic diseases: any malignancy with a life expectancy of less than one year; chronic heart failure, severe depression or other mental disorders, long-term bedridden status, or mobility limitations. 3. Experienced acute myocardial infarction or stroke within the past 6 months. 4. Acute illnesses such as upper respiratory tract infection, fever, or severe diarrhea that have not yet resolved. 5. Alcohol abuse. 6. Pregnant or breastfeeding women, or women planning to become pregnant. 7. Individuals who are deaf, mute, or have cognitive impairments that hinder communication. Phase 2: N-of-1 Trial Inclusion: 1. Classified as salt-sensitive or salt-resistant through the Phase 1 screening: 2. Salt-Sensitive (SS) Group: Participants with a change in mean arterial pressure (ΔMAP) ≥ 5 mmHg and in the upper 1/6 of the distribution of ΔMAP from the salt sensitivity test. 3. Salt-Resistant (SR) Group: Participants with a change in mean arterial pressure (ΔMAP) \< 5 mmHg and in the lower 1/6 of the distribution of ΔMAP from the salt sensitivity test. 4. Signed informed consent for the n-of-1 trial. Exclusion: 1. Failed to complete the salt sensitivity test as required, or consumed less than 80% of the study-provided meals during the salt sensitivity test (i.e., fewer than 34 meals over 14 days). 2. Experienced adverse events during the salt sensitivity test that, in the investigator's judgment, make it inappropriate to continue in the study.

Transition Care for FEP

NCT07713849
Recruiting
Conditions Schizoaffective Disorders, Bipolar Disor...
Phase Not Applicable
Enrollment 75
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care. Many patients lose contact with services after they leave the hospital, which can lead to worse outcomes. The investigators have developed a Transition Care Team (TCT) that works with patients while they are in the hospital and continues to support them after discharge. The team provides therapy, case management, and coordination with community programs that offer ongoing care. The main goal of the study is to find out if this new program increases the number of patients who successfully begin outpatient treatment after hospitalization, compared to usual care. The investigators will also look at whether the program improves symptoms, functioning, and overall well-being.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Transition Care Team — The novel intervention is the Transition Care Team (TCT), a multidisciplinary clinical support model designed to improve continuity of care for individuals experiencing a first episode of psychosis. The TCT provides short-term post-discharge services, including psychoeducation, case management, peer support, and coordination with outpatient programs until participants are established in Coordinated Specialty Care (CSC). This differs from standard care, where patients typically receive discharge referrals without structured follow-up. The intervention itself uses evidence-based clinical practices but applies them in a new, transitional format for this population, which is not currently part of standard inpatient-to-outpatient care at UChicago or Ingalls.

Primary Outcomes

  • Effectiveness of Transition Care Team for First Episode Psychosis (6 weeks post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-06
Completion: 2029-05-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Collaborators: Sidney R. Baer, Jr. Foundation
Principal Investigators:
  • Molly Erickson, PhD (PRINCIPAL_INVESTIGATOR) - University of Chicago
  • Carolyn Shima, PhD (PRINCIPAL_INVESTIGATOR) - University of Chicago
  • Sarah Keedy, PhD (PRINCIPAL_INVESTIGATOR) - University of Chicago
Contact Information
Study Contact:
Madeline Perez Lab Manager, B.S
773-712-9178
keedylab@gmail.com
Madeline Perez, B.S
773-712-9178
maddieg@bsd.uchicago.edu
University of Chicago Ingalls Memorial Hospital
Carolyn Shima, PhD
University of Chicago Ingalls Memorial Hospital
Interventions
  • Behavioral: Transition Care Team — The novel intervention is the Transition Care Team (TCT), a multidisciplinary clinical support model designed to improve continuity of care for individuals experiencing a first episode of psychosis. The TCT provides short-term post-discharge services, including psychoeducation, case management, peer support, and coordination with outpatient programs until participants are established in Coordinated Specialty Care (CSC). This differs from standard care, where patients typically receive discharge referrals without structured follow-up. The intervention itself uses evidence-based clinical practices but applies them in a new, transitional format for this population, which is not currently part of standard inpatient-to-outpatient care at UChicago or Ingalls.
Study Locations (2 sites)
University of Chicago Medical Center, Biological Science Division, Chicago, Illinois 60637 United States
University of Chicago Ingalls Memorial Hospital, Harvey, Illinois 60426 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, major depressive disorder with psychotic features, schizophreniform disorder, or psychosis NOS * The diagnosis of one of the psychotic disorders has a duration of less than two years. * Able to read, speak, and understand English, which will be assessed through observation. * Able and willing to provide written informed consent or assent, in cases where caregivers are considered legal guardians. Dr. Shima, co-I of the study, is a forensic psychiatrist, and particularly adept at judging such ability. Drs. Erickson and Keedy have conducted studies in individuals with psychotic disorders, including FEP and in the context of clinical trials, for years, and are similarly competent to judge whether individuals can provide informed consent. Finally, we will also use an Evaluation to Sign Consent form that documents subjects' verbalized understanding of key aspects of the study. * have an estimated IQ of \> 65, assessed by the Wechsler Test of Adult Reading * Eligible caregivers/proxy informants must be identified by the participant or clinical team as being involved in the participant's discharge planning or follow-up care, be able to provide informed verbal consent, and be able to speak and read English sufficiently to complete study questionnaires. Caregivers may include family members, close supports, or legally authorized representatives. Exclusion Criteria: * Individuals with substance-induced psychosis or psychosis due to a medical condition will not be included in the study. We will use the Structured Clinical Interview for DSM-5 as well as medical records, and if the subject gives permission, caregiver information in this process * Individuals who do not meet criteria for a first episode of psychosis
Conditions Major Depressive Disorder
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, rater-blinded clinical trial aims to compare the effectiveness, safety, and tolerability of accelerated intermittent theta burst stimulation (iTBS) with standard iTBS in adults with major depressive disorder (MDD). Participants will be randomly assigned in a 1:1 ratio to receive either accelerated or standard iTBS targeting the left dorsolateral prefrontal cortex. Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria. The accelerated iTBS group will receive 45 treatment sessions over approximately 15 treatment days, while the standard iTBS group will receive 20 treatment sessions over 4 weeks. The primary objective is to compare changes in depressive symptom severity, measured using the 17-item Hamilton Depression Rating Scale (HAM-D17), from baseline to the end-of-treatment assessment. Secondary and exploratory assessments include treatment response and remission, sleep quality, quality of life, cognitive measures, safety and tolerability, resting electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Accelerated Intermittent Theta Burst Stimulation — Intermittent theta burst stimulation (iTBS) is delivered to the left dorsolateral prefrontal cortex using the Beam F3 approach. Stimulation consists of triplet bursts at 50 Hz repeated at 5 Hz, with 2 seconds on and 8 seconds off. Each session consists of 1,200 pulses delivered at 100% of the resting motor threshold. Participants receive three sessions per treatment day, separated by 30 ± 5-minute intervals, over 15 treatment days, for a total of 45 sessions.
  • Device: Standard Intermittent Theta Burst Stimulation — Intermittent theta burst stimulation (iTBS) is delivered to the left dorsolateral prefrontal cortex using the Beam F3 approach. Stimulation consists of triplet bursts at 50 Hz repeated at 5 Hz, with 2 seconds on and 8 seconds off. Each session consists of 600 pulses delivered at 120% of the resting motor threshold. Participants receive one session per treatment day, 5 days per week for 4 weeks, for a total of 20 sessions.

Primary Outcomes

  • Change in 17-Item Hamilton Depression Rating Scale (HAM-D17) Score From Baseline to End of Treatment (Baseline (T0) and 24-72 hours after the final treatment session (T4))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-27
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Military Hospital 175
Contact Information
Study Contact:
Dang Minh Ly, MD
+84359999741
drminhdang@outlook.com
Dang Minh Ly, MD
+84359999741
drminhdang@outlook.com
Military Hospital 175
Interventions
  • Device: Accelerated Intermittent Theta Burst Stimulation — Intermittent theta burst stimulation (iTBS) is delivered to the left dorsolateral prefrontal cortex using the Beam F3 approach. Stimulation consists of triplet bursts at 50 Hz repeated at 5 Hz, with 2 seconds on and 8 seconds off. Each session consists of 1,200 pulses delivered at 100% of the resting motor threshold. Participants receive three sessions per treatment day, separated by 30 ± 5-minute intervals, over 15 treatment days, for a total of 45 sessions.
  • Device: Standard Intermittent Theta Burst Stimulation — Intermittent theta burst stimulation (iTBS) is delivered to the left dorsolateral prefrontal cortex using the Beam F3 approach. Stimulation consists of triplet bursts at 50 Hz repeated at 5 Hz, with 2 seconds on and 8 seconds off. Each session consists of 600 pulses delivered at 120% of the resting motor threshold. Participants receive one session per treatment day, 5 days per week for 4 weeks, for a total of 20 sessions.
Study Locations (1 sites)
Military Hospital 175, Ho Chi Minh City, 700000 Vietnam
Eligibility Criteria
Inclusion Criteria: * Age 18 to 65 years. * Right-handed. * Diagnosis of major depressive disorder according to ICD-10 criteria (F32 or F33), confirmed by a psychiatrist. * 17-item Hamilton Depression Rating Scale (HAM-D17) total score ≥18 at screening/baseline. * Able and willing to provide written informed consent and comply with essential study procedures. * Participants may be psychotropic-medication naïve or may be receiving psychotropic medication. Participants currently receiving psychotropic medication must have maintained the same medication(s) and dose(s) for at least 2 weeks before randomization; for fluoxetine, the required stable period is at least 4 weeks. Exclusion Criteria: * Intracranial or head/neck metallic foreign bodies or implants that constitute a contraindication to TMS or MRI. * Implanted electronic devices such as a cardiac pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator. * Untreated or clinically unstable thyroid dysfunction based on abnormal TSH and/or free T4 levels. * Clinically significant intracranial structural abnormalities that may affect TMS safety, neuropsychiatric presentation, or study neurophysiological measures. * History of epilepsy or seizures, except febrile seizures in childhood. * Bipolar disorder. * Other major psychiatric disorders, including schizophrenia, delusional disorder, or eating disorders. * Acute suicide risk, defined as a score ≥3 on item 3 of the HAM-D17 or clear suicidal ideation or behavior. * Alcohol or substance abuse or dependence within the previous 6 months. * A medical condition associated with a high seizure risk or a history of cranial surgery. * Current use of medication judged by the screening physician to substantially increase seizure risk, or rapid reduction/discontinuation of benzodiazepines, antiseizure medications, or other centrally acting medications associated with withdrawal or increased seizure risk. * Serum vitamin D level \<20 ng/mL that has not been adequately corrected. * Elevated C-reactive protein associated with clinically significant acute infection or acute inflammatory illness that, in the investigator's judgment, may affect participant safety or study outcome assessment. * Pregnant or breastfeeding. * Unable to understand or complete essential study procedures. Participants with potentially reversible temporary exclusion conditions may be rescreened once the condition has been adequately corrected or clinically stabilized.
Conditions Bronchial Asthma
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Acupuncture — The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days.
  • Drug: Standard Western medicine treatment — Evaluate and manage in accordance with the Chinese Expert Consensus on Assessment and Management of Acute Exacerbation of Bronchial Asthma issued by the Asthma Group of the Chinese Thoracic Society, Chinese Medical Association in 2018 and the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 ).

Primary Outcomes

  • Peak Expiratory Flow(PEF) (After treatment on Day 5 and follow-up at 1, 2 and 3 months)
  • Asthma Control Test (After treatment on Day 5 and follow-up at 1, 2 and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan University of Traditional Chinese Medicine
Contact Information
Study Contact:
Qinmei Yang
15981845716
yangqinmei840105@126.com
Qinmei Yang
15981845716
yangqinmei840105@126.com
the First Affiliated Hospital of Henan University of Chinese Medicine
Interventions
  • Other: Acupuncture — The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days.
  • Drug: Standard Western medicine treatment — Evaluate and manage in accordance with the Chinese Expert Consensus on Assessment and Management of Acute Exacerbation of Bronchial Asthma issued by the Asthma Group of the Chinese Thoracic Society, Chinese Medical Association in 2018 and the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 ).
Study Locations (1 sites)
the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000 China
Eligibility Criteria
Inclusion Criteria: 1. Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma 2. Aged ≥ 18 years old 3. Voluntarily receive treatment and sign the informed consent form Exclusion Criteria: 1. Those who fail to meet the inclusion criteria 2. Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system 3. Pregnant or lactating women 4. Subjects enrolled but not treated per the study protocol 5. Patients who have participated in other clinical trials of medicinal products within 3 months 6. Other circumstances deemed ineligible for enrollment by researchers

Lifestyle Intervention In CKD

NCT07633145
Recruiting
Conditions Chronic Kidney Disease, Hypertension
Phase NA
Enrollment 152
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study will test whether a 12-week healthy lifestyle program offered through a cardiac rehabilitation center can help lower blood pressure and improve kidney health in adults with advanced chronic kidney disease. Participants will be randomly assigned to either routine kidney health education or take part in a program that includes healthy eating guidance, supervised exercise sessions, and wellness coaching. The goal of the study is to determine whether this program can improve blood pressure and other factors linked to worsening kidney disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Multi-component lifestyle intervention — Cardiac rehabilitation-based program including supervised exercise, DASH-based dietary counseling, and wellness support over 12 weeks.
  • Behavioral: Usual Care Control — Routine medical care in addition to 1) one 30-minute counseling session with dietician and 2) an exercise prescription

Primary Outcomes

  • Change in clinic systolic blood pressure (SBP) (Baseline, 3 months, 9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-30
Completion: 2030-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 152 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Crystal Tyson, MD, MHS (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Crystal Tyson, MD
919-660-6860
crystal.simpson@duke.edu
Susanne Danus
919-681-4453
susanne.danus@duke.edu
Sarah W Stedman Nutrition & Metabolism Center
Heather Taylor
919-684-5671
heather.l.taylor@duke.edu
Sarah W Stedman Nutrition & Metabolism Center
Interventions
  • Behavioral: Multi-component lifestyle intervention — Cardiac rehabilitation-based program including supervised exercise, DASH-based dietary counseling, and wellness support over 12 weeks.
  • Behavioral: Usual Care Control — Routine medical care in addition to 1) one 30-minute counseling session with dietician and 2) an exercise prescription
Study Locations (1 sites)
Sarah W Stedman Nutrition & Metabolism Center, Durham, North Carolina 27705 United States
Eligibility Criteria
Inclusion Criteria: * Black race; ≥18 years old * history of hypertension * SBP ≥120 or DBP ≥80 mm Hg average of three measurements at screening visit (per KDIGO recommended SBP target of \<120 mm Hg)48 * Stable anti-hypertensive medication regimen (i.e., no medication changes 4 weeks prior to enrollment); * eGFR of 15-44 ml/min/1.73m2 at screening visit * agreeable to randomization to either of the 2 study arms Exclusion Criteria: * currently receiving or needing dialysis; having received or needing a kidney transplant * acute kidney injury at time of screening * average SBP ≥ 180 mm Hg or DBP ≥ 110 mm Hg at screening * Exaggerated systolic response during ETT (e.g., SBP \>210 mmHg in men or \>190 mmHg in women) * underweight (BMI \<18.5 kg/m2) * planned weight loss surgery in 1 year * a score of 27 or higher on the BP medication adherence scale * cardiac condition that would preclude participation in aerobic exercise training, including severe ischemic heart disease (CCS Class 3 or 4 angina or evidence of ischemia at \<85% heart rate reserve on screening treadmill testing), severe heart failure (NYHA Class 3 or 4), high grade arrhythmias, severe valvular heart disease * severe asthma or chronic obstructive lung disease * musculoskeletal or neurologic conditions that would preclude participation in aerobic exercise training * a major psychiatric disorder * illicit drug abuse * current alcohol consumption \>14 drinks/week for men and \>7 drinks/week for women * pregnant or planned pregnancy within 1 year * gastric bypass surgery within the last 2 years * a life-limiting comorbid medical condition, such as cancer. * physical limitation, gait instability, or need for continuous weight-bearing support that, in the opinion of study staff, would prevent safe completion of exercise treadmill testing
Conditions Breast Cancer Females
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study plans to initiate a prospective, randomized controlled trial to investigate the optimal timing of antibody drug conjugate (ADC) therapy in the management of advanced Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer. Primary Objective: To compare the difference in PFS2 (Time from randomization to disease progression after second therapy) between antibody-drug conjugate (ADC) followed by chemotherapy versus chemotherapy followed by ADC in the treatment of advanced HER2-negative breast cancer. Secondary Objectives: To compare overall survival (OS), adverse events, patient-reported outcomes, and cost-effectiveness between the two treatment sequences. Additionally, to identify potential biomarkers predictive of benefit from frontline ADC therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Antibody drug conjugate — The selection of ADC agents will be based on the patient's molecular subtype. For Hormone receptor (HR)+/HER2-low patients, anti-HER2 ADCs such as trastuzumab deruxtecan may be used. For HR+/HER2-zero patients, TROP-2-targeted ADCs such as sacituzumab govitecan are preferred. For HR-/HER2-low patients, either anti-HER2 ADCs or Trophoblast cell surface antigen 2 (TROP-2) ADCs may be considered. For HR-/HER2-zero patients, TROP-2 ADCs will be used. The specific ADC regimen will be determined at the discretion of the investigators.
  • Drug: Chemotherapy — The chemotherapy regimen will consist of standard second-line agents such as capecitabine, eribulin, vinorelbine, or gemcitabine. The specific chemotherapy regimen will be determined at the discretion of the investigators.

Primary Outcomes

  • Progression-free survival 2 (PFS2) (Up to approximately 20 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liaoning Cancer Hospital & Institute
Collaborators: National Cancer Center, China
Principal Investigators:
  • Tao Sun (PRINCIPAL_INVESTIGATOR) - Liaoning Cancer Hospital & Institute
  • Bo Lan (PRINCIPAL_INVESTIGATOR) - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Contact Information
Study Contact:
Dan Lyu
0086-19800367870
lvdan9303@163.com
Liaoning Cancer Hospital & Institute
86-19800367870
lvdan9303@163.com
Liaoning Cancer Hospital & Institute
Interventions
  • Drug: Antibody drug conjugate — The selection of ADC agents will be based on the patient's molecular subtype. For Hormone receptor (HR)+/HER2-low patients, anti-HER2 ADCs such as trastuzumab deruxtecan may be used. For HR+/HER2-zero patients, TROP-2-targeted ADCs such as sacituzumab govitecan are preferred. For HR-/HER2-low patients, either anti-HER2 ADCs or Trophoblast cell surface antigen 2 (TROP-2) ADCs may be considered. For HR-/HER2-zero patients, TROP-2 ADCs will be used. The specific ADC regimen will be determined at the discretion of the investigators.
  • Drug: Chemotherapy — The chemotherapy regimen will consist of standard second-line agents such as capecitabine, eribulin, vinorelbine, or gemcitabine. The specific chemotherapy regimen will be determined at the discretion of the investigators.
Study Locations (1 sites)
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-75 years; 2. Histologically confirmed advanced HER2-negative breast cancer, including IHC 2+/ISH-, IHC 1+/ISH-, and IHC 0/ISH- subtypes; 3. Completed first-line combination chemotherapy for advanced/metastatic disease (specific regimen not restricted), with disease progression (PD) evaluated per RECIST criteria (HR-positive patients must have received at least one line of endocrine therapy); 4. Electrocorticography (ECOG) performance status \< 2; 5. Estimated life expectancy ≥ 12 weeks; 6. Adequate bone marrow function, defined as: * ANC ≥ 1.5 × 10⁹/L * Platelets ≥ 90 × 10⁹/L * Hemoglobin ≥ 90 g/L 7. Adequate hepatic and renal function, defined as: * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * AST or ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases) * Creatinine clearance ≥ 60 mL/min 8. Signed informed consent obtained prior to any study-related procedures or treatments, confirming the patient's willingness to participate and comply with study requirements. Exclusion Criteria: 1. Prior treatment with an ADC after disease recurrence or metastasis; 2. Pregnant or breastfeeding women; 3. No evaluable recurrent or metastatic lesions as defined by RECIST 1.1 criteria; 4. Symptomatic brain parenchymal and/or leptomeningeal metastases with symptoms not adequately controlled by treatment; 5. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, or well-controlled localized basal cell carcinoma of the skin; 6. Psychiatric disorders or other conditions that may interfere with patient compliance; 7. Recent history of serious and uncontrolled systemic diseases, such as clinically significant cardiovascular disease, pulmonary disease, metabolic disorders, or arterial/venous thromboembolic events; 8. Concurrent use of other investigational drugs, or participation in another clinical trial within 30 days prior to enrollment; 9. Known or suspected allergy to any study drug or its excipients; 10. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial.
Conditions Breast Cancer, Breast Cancer Screening
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer among women worldwide. This randomized controlled trial aims to evaluate the effect of an Instagram- and podcast-based intervention on women's breast cancer awareness, health beliefs, and breast cancer screening behaviors among women aged 20-39 years.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Double

Interventions / Regimen

  • Other: Instagram-Based Breast Cancer Awareness Intervention — Participants will follow the "Breast Health Academy" Instagram account and receive an 8-week Instagram-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE), such as "Do not forget to perform your monthly BSE" and "Remember to perform BSE this week," will be shared on Tuesdays, Thursdays, and Sundays. Stories will also be saved as highlights. No content will be shared on Fridays, and all posts and stories will be published at the same time each day.
  • Other: Instagram-Podcast-Based Breast Cancer Awareness Intervention — Participants will follow the "Breast Health Academy Plus" Instagram account and receive an 8-week Instagram- and podcast-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE) will be shared on Tuesdays, Thursdays, and Sundays and saved as highlights. In addition, one educational podcast episode developed for the intervention will be delivered weekly via Instagram direct message every Friday. All content will be provided at the same time each day throughout the intervention period.

Primary Outcomes

  • Breast Cancer Awareness Scale (Assessments will be performed at baseline and Week 8.)
  • Champion's Health Belief Model Scale in Breast Cancer Screening (Assessments will be performed at baseline and Week 8.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-06
Completion: 2026-12-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara University
Principal Investigators:
  • Baise Bicav (PRINCIPAL_INVESTIGATOR) - Yüksek İhtisas University
  • Zehra Bicav (PRINCIPAL_INVESTIGATOR) - Yüksek İhtisas University
  • Sevinç Kutlutürkan (STUDY_DIRECTOR) - Ankara University
Contact Information
Study Contact:
Baise BİCAV
0 312 329 10 10
baisebicav@gmail.com
Zehra BİCAV
0 312 329 10 10
Baise Bicav
Ankara
Interventions
  • Other: Instagram-Based Breast Cancer Awareness Intervention — Participants will follow the "Breast Health Academy" Instagram account and receive an 8-week Instagram-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE), such as "Do not forget to perform your monthly BSE" and "Remember to perform BSE this week," will be shared on Tuesdays, Thursdays, and Sundays. Stories will also be saved as highlights. No content will be shared on Fridays, and all posts and stories will be published at the same time each day.
  • Other: Instagram-Podcast-Based Breast Cancer Awareness Intervention — Participants will follow the "Breast Health Academy Plus" Instagram account and receive an 8-week Instagram- and podcast-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE) will be shared on Tuesdays, Thursdays, and Sundays and saved as highlights. In addition, one educational podcast episode developed for the intervention will be delivered weekly via Instagram direct message every Friday. All content will be provided at the same time each day throughout the intervention period.
Study Locations (1 sites)
Ankara, Ankara, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Women aged 20-39 years * Able to read and write Turkish * Turkish citizens * Have an active Instagram account and access it at least once daily * No previous diagnosis of cancer * Willing to participate and provide informed consent Exclusion Criteria: * No access to a smartphone with the Instagram application * Visual, hearing, or cognitive impairment that may prevent participation in the intervention Withdrawal Criteria: * Failure to complete the assigned podcast sessions during the intervention period * Participant request to withdraw from the study at any time
Conditions Critical Illness, Depressive Symptoms
Phase PHASE2
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depressive symptoms are common among patients admitted to the intensive care unit (ICU) and may adversely affect recovery, participation in care, treatment adherence, quality of life, and outcomes after critical illness. Conventional antidepressants have limited utility for rapidly treating depressive symptoms during an ICU admission because of their delayed onset of action and potential drug interactions in medically complex patients. Ketamine is an N-methyl-D-aspartate receptor antagonist with rapid antidepressant effects when administered intravenously at subanesthetic doses. However, evidence regarding its efficacy and safety for depressive symptoms developing during critical illness remains limited. The KID-ICU trial is a Phase II randomized, double-blind, placebo-controlled, multicenter trial evaluating subanesthetic intravenous ketamine for moderate-to-severe depressive symptoms in adult ICU patients. Eligible participants are adults who have been admitted to an ICU for 6 or more days and have a Patient Health Questionnaire-9 (PHQ-9) score of 10 or greater. Participants will be randomized in a 1:1 ratio to receive either intravenous ketamine at 0.5 mg/kg, with a maximum dose of 60 mg per infusion, administered over 60 minutes once daily for 2 consecutive days, or normal saline placebo with an identical volume, appearance, and infusion duration. The primary efficacy outcome is the change in PHQ-9 total score from baseline to Day 14 after the second scheduled infusion. Secondary outcomes include the longitudinal trajectory of PHQ-9 scores through Day 30, clinically meaningful PHQ-9 response at Day 14, anxiety and depressive symptoms assessed with the Hospital Anxiety and Depression Scale, Clinical Global Impression scores, prespecified safety events, time to ICU and hospital discharge alive, and 30-day all-cause mortality. A total of 50 participants will be enrolled across participating ICUs in Argentina. Psychiatric and clinical follow-up will be provided to all participants regardless of treatment assignment.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Ketamine (0.5 mg/kg) — Ketamine hydrochloride for injection, diluted in 100 mL normal saline. Dose: 0.5 mg/kg (maximum 60 mg per infusion). Route: intravenous. Rate: infused over 40-60 minutes. Frequency: once daily. Duration: 2 consecutive days. Total maximum cumulative dose: 120 mg. Administered via peripheral or central venous catheter under continuous monitoring in the ICU.
  • Other: Normal Saline (0.9% NaCl) — Normal saline (0.9% NaCl) in 100 mL bag, identical in appearance to the ketamine preparation. Infused over 40-60 minutes, once daily for 2 consecutive days. Administered via peripheral or central venous catheter.

Primary Outcomes

  • Change in PHQ-9 Score from Baseline to Day 14 Post-Last Infusion (From baseline (before first infusion, Day 0) to Day 14 after the last infusion)
  • Incidence of Safety Events During and After Ketamine Infusion (During infusion and up to 240 minutes after each infusion (Days 1 and 2), and at follow-up visits (Days 1, 7, 14, and 30 post-last infusion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-14
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Italiano de Buenos Aires
Collaborators: Mayo Clinic
Principal Investigators:
  • Ivan A Huespe, M.D., M.P.H. (PRINCIPAL_INVESTIGATOR) - Hospital Italiano de Buenos Aires
  • Devang K Sanghavi, M.B.B.S., M.D. (STUDY_DIRECTOR) - Mayo Clinic
  • Federico Carini, M.D. (STUDY_CHAIR) - Hospital Italiano de Buenos Aires
Contact Information
Study Contact:
Ivan A. Huespe, M.D., M.P.H.
+5493425382554
ivan.huespe@hospitalitaliano.org.ar
Devang K Sanghavi, MD
+13146408772
Sanghavi.Devang@mayo.edu
Mayo Clinic
Devang K Sanghavi, MD
Mayo Clinic
Interventions
  • Drug: Ketamine (0.5 mg/kg) — Ketamine hydrochloride for injection, diluted in 100 mL normal saline. Dose: 0.5 mg/kg (maximum 60 mg per infusion). Route: intravenous. Rate: infused over 40-60 minutes. Frequency: once daily. Duration: 2 consecutive days. Total maximum cumulative dose: 120 mg. Administered via peripheral or central venous catheter under continuous monitoring in the ICU.
  • Other: Normal Saline (0.9% NaCl) — Normal saline (0.9% NaCl) in 100 mL bag, identical in appearance to the ketamine preparation. Infused over 40-60 minutes, once daily for 2 consecutive days. Administered via peripheral or central venous catheter.
Study Locations (2 sites)
Mayo Clinic, Jacksonville, Florida 32224 United States
Hospital Italiano de Buenos Aires - Sede Central, Buenos Aires, Buenos Aires Argentina
Eligibility Criteria
\*\*Inclusion Criteria:\*\* * Age 18 to 99 years. * Male or female. * Admission to an intensive care unit for 6 or more days at the time of screening. * Moderate to severe depressive symptoms, defined as a Patient Health Questionnaire-9 score of 10 or greater at screening. * Ability to provide informed consent. \*\*Exclusion Criteria:\*\* * History of psychosis or hallucinations, as assessed by review of the electronic medical record and patient interview during screening. * History of prolonged QT interval. * History of dementia. * History of major depressive disorder before the current intensive care unit admission. * History of psychiatric diagnosis, including dissociative disorder, primary psychotic disorder, mania with psychosis, pervasive developmental disorder, cognitive disorder, or anorexia nervosa. * Known allergy to ketamine or diphenhydramine. * History of increased intracranial pressure, hypertensive hydrocephalus, or increased intraocular pressure. * Hemodynamic instability at the time of screening, defined as peripheral oxygen saturation \<95%, systolic blood pressure \<90 mmHg or \>180 mmHg, heart rate \<50 or \>120 beats/min, or respiratory rate \<10 or \>30 breaths/min. * Patient refusal to participate or to provide informed consent. * Pregnancy, postpartum period within 2 months, or breastfeeding. * Presence of intracranial mass or vascular lesion. * Altered mental status precluding informed consent. * Body weight \>115 kg or \<45 kg. * Active psychosis. * Current treatment with medications that may interfere with the N-methyl-D-aspartate receptor system, including lamotrigine, acamprosate, memantine, riluzole, or lithium. * Current treatment with aminophylline or theophylline. * Active substance withdrawal or use of hallucinogens, including cannabis, in the past month, as determined by clinical interview and urine drug screening.
Conditions Weight Management
Phase PHASE3
Enrollment 4500
Locations 325 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Elecoglipron — Elecoglipron film-coated tablet once daily
  • Drug: Placebo — Placebo matching elecoglipron film-coated tablet once daily

Primary Outcomes

  • Percent body weight loss (72 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-29
Completion: 2029-07-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • Prof. Melanie Davies, MBChB (PRINCIPAL_INVESTIGATOR) - Diabetes Research Centre Leicester Diabetes Centre - Bloom University of Leicester
  • Dr. Ania Jastreboff, MD, PhD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Elecoglipron — Elecoglipron film-coated tablet once daily
  • Drug: Placebo — Placebo matching elecoglipron film-coated tablet once daily
Study Locations (325 sites)
Research Site, Birmingham, Alabama 35205 United States
Research Site, Dothan, Alabama 36305 United States
Research Site, Chandler, Arizona 85225 United States
Research Site, Sun City, Arizona 85373 United States
Research Site, Little Rock, Arkansas 72205 United States
Research Site, Lynwood, California 90262 United States
Research Site, Rolling Hills Estates, California 90274 United States
Research Site, Sacramento, California 95821 United States
Research Site, Arvada, Colorado 80002 United States
Research Site, New Haven, Connecticut 06519 United States
Eligibility Criteria
Inclusion Criteria * Legal age of consent and at least 18 years old * Study 1 - * BMI ≥ 30 kg/m2 or * 25 kg/m2 ≤ BMI \< 30 kg/m2 with at least one of the following weight-related comorbidities: * Hypertension * Prediabetes * Dyslipidemia * Cardiovascular disease * Obstructive sleep apnea. * Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below: * Established diagnosis of T2DM * Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit * Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change) * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Study 1 - Established diagnosis of T1DM or T2DM. * Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes: * T1DM * HbA1c ≥ 10% (86 mmol/mol) at the screening visit * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema. * Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis * History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
Conditions Metastatic Pancreatic Ductal Adenocarcin...
Phase PHASE1
Enrollment 66
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DFC413, and in Part 2 compare to \[68Ga\]Ga-NNS309 in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC), colorectal cancer (CRC), and soft tissue sarcoma (STS). In Part 2 of this study (comparison of \[68Ga\]Ga-DFC413 and \[68Ga\]Ga-NNS309), not all indications might be explored.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 68Ga-DFC413 — Radioimaging agent
  • Drug: 68Ga-NNS309 — Radioimaging agent

Primary Outcomes

  • Part 1: Standard Uptake Value (SUV) of 68Ga-DFC413 uptake in organs and tumors over time (Up to 240 minutes after 68Ga-DFC413 administration)
  • Part 1: Standard Uptake Value ratio (SUVr) of 68Ga-DFC413 uptake (Up to 240 minutes after 68Ga-DFC413 administration)
  • Part 2: Agreement between 68Ga-DFC413 and 68Ga-NNS309 for assessing target lesions from both PET scans per disease group (Up to 240 minutes after administration of each imaging agent)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-23
Completion: 2028-01-16
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
Interventions
  • Drug: 68Ga-DFC413 — Radioimaging agent
  • Drug: 68Ga-NNS309 — Radioimaging agent
Study Locations (2 sites)
Novartis Investigative Site, Odense C, 5000 Denmark
Novartis Investigative Site, Chuo Ku, Tokyo 1040045 Japan
Eligibility Criteria
Inclusion Criteria: Patients eligible for inclusion in this study must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Age ≥ 18 years old. 3. ECOG performance status ≤ 2. 4. Patients with one of the following indications (regardless of lines of prior therapy): Locally advanced unresectable or metastatic PDAC, NSCLC, HR+/HER2- ductal or lobular BC, TNBC, CRC or STS. 5. Patients must have at least one measurable lesion per RECIST v1.1 as measured by local Investigator (by conventional MRI or CT scan). 6. Patients must have an available archival tumor sample at the screening visit. If multiple archival tumor samples are available, the most recent will be requested. Exceptions may be made after documented discussion with Novartis. Exclusion Criteria: Patients meeting any of the following criteria are not eligible for inclusion in this study: 1. Out-of-range laboratory values defined as: * Estimated glomerular filtration rate \< 60 mL/min (calculated using CKD-EPI 2021 formula, or measured based on 24-hour urine collection) * Total bilirubin \> 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 x ULN) or direct bilirubin \> 1.5 x ULN * Alanine aminotransferase (ALT) \> 3.0 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT \> 5.0 x ULN * Aspartate aminotransferase (AST) \> 3.0 x ULN, except for patients with tumor involvement of the liver who are excluded if AST \> 5.0 x ULN * Absolute Neutrophil Count \< 1.0 x 109/L * Hemoglobin \< 9 g/dL * Platelet count \< 75 x 109/L 2. Unmanageable urinary tract obstruction or urinary incontinence. If ureteral obstruction can be managed with the placement of ureteral stents, this exclusion criterion does not apply. 3. Known hypersensitivity to 68Ga-DFC413 or 68Ga-NNS309 or their excipients. 4. Any serious uncontrolled infection (acute or chronic), such as, but not limited to, bacterial, viral or fungal infections, confirmed by clinical evidence, imaging, and/or relevant positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA). If a serious infection develops, it must resolve or be adequately controlled prior to 68Ga-DFC413 and/or 68Ga-NNS309 initiation. 5. Surgery or major invasive procedure within 4 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 6. Radiation therapy within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 7. Change in anticancer therapy within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 8. Radiological contrast administration within 48 hours prior to 68Ga-DFC413 or 68Ga-NNS309 administration. 9. Initiation or increasing doses of corticosteroids, TGF-β signaling inhibitors or immunomodulators within 2 weeks prior to 68Ga-DFC413 or 68Ga-NNS309 administration or between the two imaging agents. 10. Known additional malignancy that is progressing or requires active treatment. 11. Inability to complete the required investigational and standard imaging examinations due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time). 12. Presence of CTCAE version 5.0 ≥ Grade 2 toxicity due to prior cancer therapy, except for neuropathy (inclusion of patients with neuropathy of ≤ Grade 2 is permitted) and alopecia. 13. Any medical condition that would, in the Investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures (including radiation safety precautions), or interpretation of study results. 14. Pregnant women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 15. Nursing (breast-feeding) women. Women who do not breast feed for 12 hours after 68Ga-DFC413 and/or 68Ga-NNS309 administration, but express and discard breast milk, are eligible. 16. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they use highly effective methods of contraception (failure rate \<1% per year) for 12 hours after the administered radioactive dose of 68Ga-DFC413 and 68Ga-NNS309. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms). Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Bilateral tubal ligation, female sterilization (have had bilateral oophorectomy with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking 68Ga-DFC413 or 68Ga-NNS309. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they considered to be not of childbearing potential. * Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient. * Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example, hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent (IC). 17. Sexually active males unwilling to use a condom during intercourse for 12 hours after the administered radioactive dose of 68Ga-DFC413 and 68Ga-NNS309. A condom is required for all sexually active male patients to prevent them from fathering a child and/or to prevent delivery of study treatment via seminal fluid to their partner. In addition, male patients must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the IC. Other protocol-defined inclusion/exclusioncriteria may apply.
Conditions HER2-positive Breast Cancer
Phase PHASE3
Enrollment 228
Locations 70 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GQ1005 — Administered I.V.
  • Drug: T-DM1 — Administered I.V.

Primary Outcomes

  • Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-10
Completion: 2028-01-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 228 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.
Principal Investigators:
  • Zefei Jiang, M.D. (PRINCIPAL_INVESTIGATOR) - The Fifth Medical Center of the Chinese People's Liberation Army General Hospital
Contact Information
Study Contact:
Zhenxing Yang
+86 13801896162
yangzx@genequantum.com
Zhang Mingliang
The First Affiliated Hospital of Bengbu Medical University
Yingying Du
The Affiliated Fuyang Hospital of Anhui Medical University
Interventions
  • Drug: GQ1005 — Administered I.V.
  • Drug: T-DM1 — Administered I.V.
Study Locations (70 sites)
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004 China
The Affiliated Fuyang Hospital of Anhui Medical University, Fuyang, Anhui 236000 China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001 China
Anhui Cancer Hospital, Hefei, Anhui 230031 China
The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, Beijing Municipality 100071 China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality 400030 China
Fujian Cancer Hospital, Fuzhou, Fujian 350014 China
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000 China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060 China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: * Male or female adults ≥ 18 years at the time of voluntary signing of informed consent. * Pathologically confirmed unresectable or metastatic HER2 positive breast cancer previously treated with trastuzumab and taxane * Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. * Presence of at least one measurable lesion according to RECIST v1.1 * Expected survival time ≥ 12 weeks. * Patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. Exclusion Criteria: * Prior anti-HER2 ADC therapy. * Previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring steroid therapy. * Known serious hypersensitivity to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs. * Multiple primary malignancies within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer * Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, autoimmune disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult * Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 (NCI-CTCAE v5.0) or baseline.